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In eukaryotes, RNA Polymerase (Pol) III is specialized for the transcription of tRNAs and
other short, untranslated RNAs. Pol III is a determinant of cellular growth and lifespan across
eukaryotes. Upregulation of Pol III transcription is observed in cancer and causative Pol III
mutations have been described in neurodevelopmental disorders and hypersensitivity to viral
infection. Here, we report a cryo-EM reconstruction at 4.0 Å of human Pol III, allowing
mapping and rationalization of reported genetic mutations. Mutations causing neurodeve-
lopmental defects cluster in hotspots affecting Pol III stability and/or biogenesis, whereas
mutations affecting viral sensing are located in proximity to DNA binding regions, suggesting
an impairment of Pol III cytosolic viral DNA-sensing. Integrating x-ray crystallography and
SAXS, we also describe the structure of the higher eukaryote specific RPC5 C-terminal
extension. Surprisingly, experiments in living cells highlight a role for this module in the
assembly and stability of human Pol III.
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Transcription of the eukaryotic genome is mediated by threehighly specialized nuclear RNA polymerase (Pol) enzymes.Pol III transcribes short untranslated RNAs, which are
essential for cellular functions, such as the entire pool of transfer
RNAs, the precursor of the 5S ribosomal RNA and the
U6 spliceosomal RNA1.
Pol III is a multi-subunit complex composed of 17 subunits. A
central ten-subunit core, which harbours the catalytic site and a
peripheral heterodimeric stalk that are structurally conserved among
the three eukaryotic Pols. The TFIIF-like RPC4/5 and the TFIIE-like
RPC3/6/7 subcomplexes are Pol III specific and can be regarded as
built-in general transcription factors that play a fundamental role in
Pol III transcription initiation and termination2–4.
Across the eukaryotic kingdom, Pol III displays a high degree
of conservation both in terms of subunit composition and
sequence homology of the individual components. A notable
exception is the subunit RPC5, which in metazoans encompasses
a long C-terminal extension (RPC5EXT, ~450 residues long),
whose function is currently unknown.
Pol III activity is highly regulated in a cell cycle and cell-type-
dependent manner5, and is a determinant of lifespan in eukar-
yotes6. In recent years, a large number of disease-causing muta-
tions have been assigned to Pol III subunits, with a particular
incidence of allele variants that strongly affect the correct devel-
opment of the central nervous system (CNS), resulting in severe
neurodegenerative diseases7–14. Furthermore, causative Pol III
mutations have also been described in patients affected by
hypersensitivity to viral infection15,16.
To date, yeast Pol III has been extensively structurally and
functionally characterized, while its human counterpart has been
left relatively untouched, due to the inherent technical challenges
in obtaining yields amenable for structural biology. However,
understanding the specific influence of pathological mutations
and the role of regulatory elements unique to the human enzyme
relies on such structural information. Here, we report the cryo-
genic electron microscopy (cryo-EM) reconstruction of human
Pol III. We further study the enzymes’ complete architecture
using a structural biology hybrid approach integrating two crystal
structures of the human RPC5 C-terminal extension, as well as
SAXS data and molecular modelling. Results of our comparative
structural analysis rationalize the effect of pathological mutations
and yield unexpected insights into Pol III regulation.
Results
Purification of human RNA Pol III. To obtain a high-resolution
structure of human Pol III, we isolated the endogenous complex
from HeLa cells. To this end, we employed CRISPR/Cas9 genome
editing in human cells to create a homozygous knock-in of a
cleavable green fluorescent protein (GFP)-tag at the C terminus of
subunit RPAC1 (shared between Pol I and Pol III) (Fig. 1a).
Fractionation experiments followed by immunopurification using
an anti-GFP nanobody revealed that Pol III is present in both
nuclear and cytoplasmic fractions (Fig. 1b), in agreement with
previous reports highlighting a Pol III cytosolic DNA-sensing
activity17,18. An optimized large-scale purification, including an
ion-exchange step to separate Pol I and Pol III, enabled the iso-
lation of active human Pol III (Fig. 1c, d and Supplementary
Fig. 1) from total cell extracts with yields and quality amenable
for further EM studies.
Fig. 1 Purification of GFP-tagged endogenous human RNA polymerase III. a Confocal imaging of modified HeLa cell line expressing homozygous sfGFP-
tagged POLR1C gene. Endogenous GFP signal, representing Pol I and III (green), DAPI staining (magenta) and overlay of both channels are shown. Scale
bar: 5 µm. Shown is a representative image of four independent experiments. b Affinity-purified human RNA Pol III from HeLa nuclear and cytoplasmic
fractions. Confirmed RNA Pol subunits are labelled. Shown is a representative image of two separate experiments. c Purified human RNA Pol III (hPol III)
from large-scale whole-cell lysate with Pol III subunits marked. Shown is an excised lane of a representative image of three separate purifications. d RNA
extension assay of fluorescently labelled FAM-15mer RNA primer by purified human Pol III. Marked is Pol III-mediated primer extension. The molecular
marker displays expected sizes for 15 and 21 nucleotides (nt). Displayed is a representative image of seven independent repeats. Source data are provided
as a Source Data file.
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Cryo-EM structure of human Pol III. The non-crosslinked
purified human Pol III sample was applied to carbon-coated cryo-
EM grids and imaged on a Titan Krios TEM microscope equipped
with a Falcon III camera. Two data sets were collected at 0° and
30° tilting angles, to overcome preferred orientation of the sample
on the cryo-grids, resulting in a merged dataset of 172,678 par-
ticles after two-dimensional (2D) class averaging (Supplementary
Fig. 2 and Table 1). The majority of imaged particles represented
the intact 17-subunit human Pol III but a sizeable fraction with a
similar angular distribution displayed no density for the RPC3/6/7
heterotrimer, which had possibly dissociated during purification,
in agreement with earlier reports19, or during cryo-EM specimen
preparation. Hierarchical three-dimensional (3D) classification led
to a reconstruction of the intact human Pol III from 25,369 par-
ticles at an overall resolution of 4.0 Å (Supplementary Figs. 2 and
3, and Table 1). The core of the enzyme is characterized by a very
detailed EM map where side chains are clearly discernible (Fig. 2).
The RPC8/9 stalk and the RPC3/6/7 subcomplex are more flexible
than the core; hence, their local resolution is lower compared to
the rest of the complex (Supplementary Fig. 3). Interestingly, the
coiled-coil region of the clamp subdomain within the largest
subunit RPC1, which is in direct contact with the RPC3/6/7 het-
erotrimer, also displays a high degree of flexibility. This finding
suggests that the coiled-coil region of the clamp together with the
heterotrimer form a discrete structural and functional unit, which
in yeast has been shown to be able to sense melting of the
upstream side of the transcription bubble4.
As can be expected from the high degree of sequence
conservation, the overall structure of human Pol III resembles
the yeast counterpart. Structure-based alignments and compar-
ison revealed that most subunits share a high degree of similarity
and low root-mean-squared deviation values (Supplementary
Fig. 4). However, local differences highlight specific features that
might be relevant for human-specific regulation and correct
assembly of the Pol III enzyme. Three relevant deletions were
Fig. 2 The structure of human RNA polymerase III. Shown is the electron density map filtered according to the local resolution with the fitted model
shown in ribbon representation (above). Regions of the electron density map are coloured according to the subunit structure as labelled. Shown below are
selected regions of several subunits showing the fit with the filtered electron density (mesh).
Table 1 Cryo-EM data collection, refinement and validation
statistics.
Data collection (0° Tilt)
Voltage (kV) 300
Electron exposure (e−/Å2) 44.1
Defocus range (μm) −1.0 to −3.0
Pixel size (Å) 1.065
Data collection (30° Tilt)
Voltage (kV) 300
Electron exposure (e−/Å2) 37.8, 40.6
Defocus range (μm) −1.2 to −3.0
Pixel size (Å) 1.065
Reconstruction (RELION)
Initial particle images (no.) 172,678
Final particle images (no.) 25,369
Map resolution (Å) 4.0
FSC threshold (0.143-thr)







Bond lengths (Å) 0.016
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observed in the human RPC1 sequence in both the jaw and foot
domains. The deletion in the jaw domain removed a small
unstructured loop (Supplementary Fig. 5), whereas two deletions
in the human RPC1 foot domain result in a rearranged, more
compact foot structure (Supplementary Fig. 5). Interestingly,
similar structural rearrangements have been observed in the
mammalian Pol II foot domain, a region that provides a binding
interface for auxiliary regulators such as the DSIF and the PAF
complex20,21.
In human RPC4, a small deletion removed a helix (residues
269–285), which in the yeast RPC4 protrudes back towards the Pol
core and contacts RPC2 (Supplementary Fig. 5). Deletion of this
region may therefore highlight a weaker association between the
human RPC4/5 heterodimer and core when compared to the yeast
enzyme. In the RPC5 dimerization module, structural alignment
detected the insertion of a small loop in humans in addition to the
large C-terminal insertion (RPC5EXT), which together suggest a
slightly rearranged heterodimer module in human Pol III (Supple-
mentary Fig. 5). Furthermore, comparison of the yeast and human
stalk subunit RPC9 identified two additional deletions in the human
structure which remove unstructured loops (not present in the cryo-
EM map of the corresponding yeast subunit). This comparative
analysis of the Pol peripheral subcomplexes was limited in the human
structure due to the flexibility of the RPC5EXT and heterotrimer-
clamp module. As a result, both the reported RPC3 iron-sulphur
cluster22 and the RPC5EXT, elements absent in the Saccharomyces
cerevisiae Pol III structures3,4,23, were not visible in our EM map.
Structure of the RPC5 C-terminal extension. To gain insight
into the structure and function of RPC5EXT, we determined the
structure of its individual domains by X-ray crystallography (Sup-
plementary Fig. 6, Fig. 3, and Tables 2 and 3). The RPC5EXT is
formed by two consecutive tandem winged helix domains (tWHD1
residues 259–440; tWHD2 residues 556–708) connected by a 115
residue-long flexible linker. Such an architecture has not been
reported for other components of the eukaryotic transcription
apparatus and appears to be found exclusively in metazoan RPC5.
Of the two tWHDs, tWHD1 is the most conserved while tWHD2 is
absent in Caenorhabditis elegans and Drosophila melanogaster
(Supplementary Fig. 7). The tWHD1 is formed by two juxtaposed
winged helix domains that form a compact globular domain with
one of the two recognition helices, typically involved in DNA
binding, buried within the structure (Fig. 3b). The compact con-
formation of tWHD1 is observed also in solution as highlighted by
small-angle X-ray scattering (SAXS) data (Fig. 3d and Supple-
mentary Fig. 6). The tWHD2 structure revealed a dimer formed by
Fig. 3 Structure of the RPC5 subunit C-terminal region. a Domain architecture of RPC5 C terminus. tWHD1 and tWHD2 are coloured in red and green
shades, respectively. Regions are depicted according to their presence (black line) or absence (black dashed line) in the crystal structures. DM refers to
RPC5 dimerization module. b Crystallographic model of RPC5-WHD1 (dark red), RPC5-WHD2 (light red) and the linker regions (grey) in ribbon cartoon.
Inset shows detail of the electron density map. c Overall structure of RPC5-tWHD2 crystallographic packing in ribbon cartoon. RPC5-WHD3 and RPC5-
WHD4 are shown in dark and light green, respectively, and the inset shows detail of the electron density map. d Fitting of RPC5-tWHD1 (red, inset) into
the SAXS experimental data (black). e Fitting of RPC5-tWHD2 in ‘closed’ (green, inset), ‘open’ (dashed green) and dimer (orange) conformations into the
SAXS experimental data (black). f Docking of RPC5-tWHD1 (red) and RPC5-tWHD2 (green) into the ab initio SAXS envelope generated from RPC5EXT
SAXS data collection.
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domain swapping (Fig. 3c). This arrangement is likely caused by the
crystallization conditions and, in agreement with this hypothesis,
SAXS data showed a monomeric conformation as the most likely in
solution (Fig. 3e and Supplementary Fig. 6). Nevertheless, the two
possible conformations of tWHD2, compact or elongated, suggests
a degree of flexibility within this domain. Finally, SAXS analysis of a
construct encompassing the full-length RPC5EXT support the
model of two globular compact tWHD domains connected by a
long flexible linker, spanning approximately up to 175Å in length
(Fig. 3f and Supplementary Figs. 8 and 9).
Comparison with existing protein structures using the Dali
server (http://ekhidna.biocenter.helsinki.fi/dali_server/) suggested
similarities between tWHD1 and the WHD of S. cerevisiae Pol II
general transcription factor TFIIF Rap30 subunit24–26 and with
the tWHD of Pol I A49 subunit27–31. Both subunits are orthologs
of RPC5 and involved in stabilization of the pre-initiation
complexes (PICs), suggesting a putative functional link. However,
although the position of TFIIF Rap30 WHD in the Pol II PIC
clashes with the Bdp1 subunit of transcription factor TFIIIB in the
Pol III PIC3,4 (Fig. 4), the equivalent position of A49 tWHD in the
Pol I PIC27 is accessible in the Pol III PIC (Fig. 4). Thus, one
possibility is that, analogously to A49 tWHD, the RPC5-tWHD1
participates in an interaction with the upstream DNA and bound
transcription factors, thus stabilizing the human Pol III PIC. In
Table 2 RPC5-tWHD1 (aa. 259–440) data collection, phasing and refinement statistics for MAD (SeMet) structures.
Crystal 1 (Native) Crystal 2 (SeMet)
Data collection
Space group P6122 P6122 P6122 P6122
Cell dimensions
a, b, c (Å) 56.30, 56.30, 275.88 56.43, 56.43, 277.27 56.44, 56.44, 277.17 56.41, 56.41, 276.95
α, β, γ (°) 90, 90, 120 90, 90, 120 90, 90, 120 90, 90, 120
Peak Inflection Remote
Wavelength 0.91983 0.97965 0.97980 0.971970
Resolution (Å) 48.01–2.23 (2.29–2.23) 48.87–2.72 (2.79–2.72) 48.88–2.63 (2.70–2.63) 48.11–2.50 (2.56–2.50)
Rsym or Rmerge 0.05 (0.749) 0.324 (2.163) 0.268 (1.820) 0.246 (1.656)
I/σI 26.9 (5.7) 8.7 (1.5) 9.4 (1.5) 8.7 (1.2)
Completeness (%) 100.0 (100.0) 100.0 (100.0) 100.0 (100.0) 100.0 (100.0)
Redundancy 27.4 (28.8) 21.6 (19.6) 21.2 (15.8) 20.0 (10.6)
Refinement
Resolution (Å) 45.97–2.23 (2.31–2.23)
No. reflections 376,023
Rwork/Rfree 0.1800/0.2193









Bond lengths (Å) 0.008
Bond angles (°) 0.84
Table 3 Rpc5-tWHD2 (aa. 556–708) data collection, phasing and refinement statistics for MAD (SeMet) structures.
Crystal 1 (SeMet) Crystal 2 (SeMet)
Data collection
Space group P1 21 1 P1 21 1 P1 21 1 P1 21 1
Cell dimensions
a, b, c (Å) 41.11, 75.76, 62.4 41.37, 75.67, 62.77 41.35, 75.78, 62.79 41.30, 75.72, 62.67
α, β, γ (°) 90.0, 103.57, 90.0 90.0, 103.73, 90.0 90.0, 103.72, 90.0 90.0, 103.64, 90.0
Peak Inflection Remote
Wavelength 0.97942 0.97942 0.97957 0.97174
Resolution (Å) 30.33–1.48 (1.52–1.48) 47.48–1.74 (1.79–1.74) 47.52–1.71 (1.75–1.71) 60.90–1.78 (1.83–1.78)
Rsym or Rmerge 0.075 (0.735) 0.095 (0.942) 0.088 (0.954) 0.118 (1.001)
I/σI 11.8 (1.3) 10.5 (1.6) 11.2 (1.5) 9.0 (1.5)
Completeness (%) 96.1 (71.2) 99.9 (100.0) 99.9 (100.0) 99.9 (100.0)
Redundancy 6.1 (3.6) 6.7 (5.8) 6.7 (5.4) 6.8 (6.4)
Refinement
Resolution (Å) 30.33–1.55 (1.60–1.55)
No. reflections 364,951
Rwork/Rfree 0.1786/0.2078









Bond lengths (Å) 0.011
Bond angles (°) 1.15
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addition, the Dali server analysis retrieved similarities between the
individual WHDs of RPC5EXT tWHD2 and the WHDs of cullin
and cullin-like proteins, which are involved in ubiquitin-
dependent proteolysis32.
The RPC5 extension is required for RNA Pol III stability. To
gain insight into the functional role of RPC5EXT, we used small
interfering RNA (siRNA) to knock down RPC5 in HEK293T cells
and rescued it with ectopic expression of haemagglutinin (HA)-
tagged RPC5 constructs encompassing the full-length protein
(RPC5FL) or a version of RPC5 devoid of either tWHD2
(RPC5ΔtWHD2) or the entire RPC5EXT (RPC5ΔC) (Supple-
mentary Fig. 10a, b). Immunoprecipitation using anti-HA mag-
netic beads revealed that both RPC5FL, RPC5ΔtWHD2 and
RPC5ΔC are able to integrate into and pull down a bona fide
intact Pol III complex, as probed by RPC1, RPC2 and RPC4
antibodies (Supplementary Fig. 10c). However, the corresponding
immunoblots of whole-cell extracts, prior to the immunopreci-
pitation, indicate lower steady-state levels of RPC5ΔC compared
to RPC5FL, pointing towards a direct role of RPC5EXT in
enhancing RPC5 stability. To further explore the role of
RPC5EXT in regulating RPC5 stability in the context of an intact
Pol III complex, we employed a cycloheximide chase assay
(Fig. 5). Levels of RPC5FL remained stable for the course of the
experiment (8 h), as well as subunits RPC1 and RPC2, suggesting
a relatively long half-life of the Pol III complex (Fig. 5a). On the
contrary, RPC5ΔtWHD2 and RPC5ΔC were rapidly degraded
with RPC5ΔC almost completely depleted after only 2 h following
cycloheximide treatment (Fig. 5b, c). Surprisingly, subunits RPC2
and, to a minor extent, RPC1 and RPC4 were also rapidly
depleted, suggesting that RPC5EXT is essential for the stability of
the whole Pol III complex.
Pathological genetic mutations map to Pol III subunit inter-
faces. Many studies have reported mutations of the Pol III
enzyme that are related to human diseases, in particular heritable
diseases, which affect the correct development of the CNS. Spe-
cifically, allele variants encoding mutated versions of the Pol III
subunits RPC1, RPC2, RPAC1 and RPAC2 subunits have been
established as causative mutations of hypomyelinating leukody-
strophy (HL)7–10,33–37, Treacher–Collins syndrome (TCS)11,12
and Wiedemann–Rautenstrauch syndrome (WRS)13,14.
To rationalize these findings, we mapped known Pol III
mutations on our high-resolution structure (Fig. 6 and
Supplementary Data 1). Reported mutations affecting CNS
development tend to cluster in specific hotspots, very often at
the interface of several Pol III subunits. For example, TCS
mutations L51R and T50I in RPAC2 result in disruption of
hydrophobic and salt-bridge interactions, respectively, at the
interface with the RPAC1 subunit, suggesting a strong destabiliz-
ing effect that might impair correct assembly of the enzyme
(Fig. 6). Analogously, most reported HL mutations lay at the
interface of several subunits and have disruptive effects on these
interfaces (Fig. 6 and Supplementary Data 1). Interestingly, WRS
mutation R1069Q in subunit RPC1 disrupts a charged interaction
with residue N1249 in the same subunit. This residue is itself
mutated in HL, possibly altering the interface between subunits
RPC1 and RPABC1 in both pathologies. Overall, these finding
indicate a general molecular mechanism from mutations resulting
in CNS disorders, which is the partial loss of function of Pol III
activity through destablization of the enzyme core.
Recently, Pol III mutations have also been described in patients
affected by acute severe response to Varicella zoster virus (VZV)
infection15,16,38. Most of these mutations map at the periphery of
the Pol III enzyme and result in neutralizing basic charged
residues exposed to the solvent in proximity of DNA-binding
regions (Fig. 6). As human Pol III has been shown to display
cytosolic DNA-sensing activity, it is conceivable that VZV
mutations indeed impair proper DNA binding and transcription
factor-independent RNA synthesis in the cytoplasm.
Overall, these findings are in agreement with previous work
using the homologous yeast Pol III, and/or Pol I and Pol II
enzymes to map disease-causing mutations8–10,15,39. However,
the availability of a high-resolution structure of human Pol III
enable the comprehensive mapping and rationalization of these
allele variants with high confidence.
Discussion
Here we describe the 4.0 Å resolution cryo-EM structure of apo
human Pol III. The structure confirms the overall high-degree of
structural homology with its S. cerevisiae counterpart but also
highlights specific differences, such as a rearranged foot domain
(Supplementary Fig. 5). Integrating cryo-EM data with X-ray
crystallographic and SAXS data for the metazoan-specific
RPC5EXT, detailed structural information has been obtained
for the whole Pol III complex (Supplementary Fig. 11). Surpris-
ingly, experiments in living cells highlighted a prominent role of
RPC5EXT for the integrity of the Pol III complex. Absent in
lower eukaryotes, RPC5EXT thus represents an additional
Fig. 4 Structural alignment of RPC5-tWHD1 to Pol I and Pol III PICs. a Structural alignment between S. cerevisiae RNA Pol II (PDB code: 5FYW) and RNA
Pol III (PDB code: 6EU0). RPC5-tWHD1 (wheat) superimposition to yeast Tfg2 WHD (grey) leads to clashes with Bdp1 subunit stem motif (orange).
b Structural alignment between S. cerevisiae RNA Pol I (PDB code: 5W66) and RNA Pol III (PDB code: 6EU0). RPC5-tWHD1 (wheat) superimposition to
yeast A49 tWHD (grey) does not cause clashes with TFIIIB subunits Brf1 (green), TBP (pink) or Bdp1 (orange).
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metazoan-specific module, impacting on the correct assembly of
Pol III. Several abundant phosphorylation sites have been iden-
tified in RPC5EXT, which, together with the evidence of struc-
tural similarities between RPC5EXT tWHD2 and factors involved
in targeted degradation, suggests the intriguing hypothesis of an
RPC5EXT-mediated layer of regulation impacting overall Pol III
abundance in response to environmental cues that may have
evolved in higher organisms.
Furthermore, the high-resolution structure of human Pol III
enabled the mapping of more than 85% of reported Pol III genetic
mutations with high precision, rationalizing their effects at a
molecular level (Supplementary Data 1). Mutations affecting the
CNS development tend to spatially cluster together and it seems
likely that the severity of the phenotypes observed in HL, TCS
and WRS correlate with the disruptive effect of such variants. For
example, TCS mutations appear to be particularly disruptive at
the interface of RPAC1 and RPAC2, two subunits shared between
Pol I and Pol III. Interestingly, mutations N32I and N74S in
RPAC1 mutations associated with HL lead to reduced Pol III
assembly and nuclear import, without affecting Pol I7. This is
consistent with our model, as these residues mediate interactions
with Pol III-specific RPC1 and RPC2, respectively (Supplemen-
tary Data 1).
Finally, as Pol III represents a central nexus involved in the
regulation of organismal growth, development and lifespan in
eukaryotes and is often deregulated in cancer, the structure of the
Fig. 5 Cycloheximide chase assay investigation of RPC5 protein stability. HEK293T cells were seeded, endogenous RPC5 was knocked down via siRNA
and either the FL a, ΔtWHD2 b, or ΔC c, RPC5 constructs were transfected. After 24 h, cycloheximide was added in at a concentration of 300 µg/ml and
cells lysed at the specified time points. RPC1, 2, 4 and 5 (as shown via HA-tag antibody) levels were probed by western blotting. Displayed images are
representative of three independent experiments. Source data are provided as a Source Data file.
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human enzyme will represent an invaluable tool to aid the design
of small molecules capable of specifically targeting Pol III tran-
scription for therapeutic purposes.
Methods
CRISPR/Cas9 genome editing. HeLa cells were cultured in Dulbecco’s modified
Eagle medium (DMEM, D6429, Sigma Aldrich) supplemented with 10% fetal
bovine serum (FBS) (P40-37500, PAN-Biotech) and 1% AAS (A5955, Sigma
Aldrich). Genomic integration of Superfolder GFP (sfGFP) ORF at the C terminus
of POLR1C was done by CRISPR/Cas9 based on a published protocol (Ran et al.40)
performed as following.
Design of the guide RNAs (gRNAs) was done with a web-based tool (http:\CRISPR.
mit.edu) and annealed oligos (gRNA1= 5′-gCTAGTTCATCCAAGAAG
CGC-3′; gRNA2= 5′-gCGGTTCAGATGGACTGAGCT-3′) were cloned via BplI into
the bicistronic Cas9n expression vector pSpCas9n(BB)−2A-Puro (PX462) V2.0, which
Fig. 6 Mapping genetic mutations in human RNA Polymerase III. a The position of residues mutated in hypomyelinating leukodystrophy (HL, green),
Treacher–Collins syndrome (TCS, orange), Wiedemann–Rautenstrauch syndrome (WRS, red) and VZV susceptibility (VZV, purple) is shown as solid
spheres. b–f The close-up panels show details of the interfaces involved in TCS (b), HL (c–e) and WRS mutations (f). Side chains are shown in stick
representation and Pol III subunits are coloured as in Fig. 2.
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was a gift from Feng Zhang (Addgene plasmid #62987: https://n2t.net/addgene:62987;
RRID: Addgene_62987). A donor plasmid carried a short GS-linker sequence with an
embedded Human Rhinovirus (HRV) 3C protease cleavage site and the sfGFP ORF
surrounded by two large sequence segments homologous to the insertion locus in the
genome.
HeLa cells were transfected with a 1 : 1 : 1 mix of gRNA1 and gRNA2 vectors
together with the donor plasmid using PolyJet transfection reagent (SL100688,
SignaGen Laboratories) according to the manufacturer’s instructions. Several days
later, the GFP-expressing cells were enriched by flow cytometry using a Bio-Rad
S3e cell sorter. GFP-positive cells were seeded on large culture dishes such that they
could grow as single cell colonies. After 2–3 weeks, colonies were transferred
manually into multi-well slides for live-cell imaging and were screened under
identical microscope settings. The brightest clones were selected for expansion.
These monoclonal populations were validated by PCR on extracted genomic DNA
(using the Blood & Tissue Kit, Qiagen).
The selected cell line was cultivated adherently and adapted to suspension
growth as follows: Cells from 8 flasks (about 70 × 106 cells total; 83.3912.302,
Sarstedt) were detached by incubation with trypsin (25,300, Gibco) at 37 °C for 5
min, transferred to a spinner flask (250 mL total volume; 4500, Corning) and
cultured in suspension with high-glucose DMEM (11965, Gibco) supplemented
with 1% FBS (10,270, Gibco) and 1% Penicillin/Streptomycin (P0781, Sigma
Aldrich) under moderate stirring at 37 °C, 5% CO2 atmosphere. To expand the
culture, 1× the current volume of fresh media including all supplements was added
when cells reached a density of ~3.5 × 105 cells/mL and transferred to spinner flasks
of increasing volume when required. Cells were collected by centrifugation and
washed with phosphate-buffered saline (PBS) before flash-freezing the pellet.
For fluorescence imaging, cells were grown adherently on cover slips to 50%
confluency. After washing the cells with pre-warmed (37 °C) PBS, they were fixed
with 3.7% paraformaldehyde in PBS for 10 min at 37 °C. The fixation was stopped
by addition of 100 mM glycine in PBS for 5 min at 37 °C and cells were washed
twice with PBS. The cells on the cover slips were mounted on the specimen slide
with the help of a drop Prolong Gold Antifade Mountant with 4′,6-diamidino-2-
phenylindole (DAPI) (P36941, Thermo Fisher Scientific) and dried for at least
3 days in the dark.
The fluorescent specimens were imaged using a Zeiss Axio Observer.Z1/7
microscope and a ×63 oil-objective lens. DAPI staining was detected with the help
of a 405 nm excitation laser and for the emission a wide band-pass filter (300–720
nm) was used. For sfGFP detection, a 488 nm laser and the same band-pass filter
(300–720 nm) was applied. The images were captured with the Airyscan mode and
detector. Processing was done using the Zeiss AxioVision software, the Zeiss ZEN
3.0 (ZEN lite) software and Fiji.
The selected homozygous cell line was further characterized by western blotting.
Cells from a confluent 6 cm plate (about 2.7 × 106 cells, 83.3901.300, Sarstedt) were
collected with 300 µl of boiling 1× SDS loading dye (3% (w/v) glycerol, 1.68% (v/v)
β-mercaptoethanol, 0.03% (w/v) bromophenol blue, 26 mM Tris pH 6.8, 0.42 %
(w/v) SDS) and rigorously shaken at 95 °C for 15 min. Prestained Marker (7719 S,
NEB) and 10 µl of sample from the parental and the newly generated cell line were
loaded on a SDS gel (NP0223BOX, Thermo Fisher Scientific) and proteins
separated by electrophoresis. After blotting (Trans-Turbo Blot, Bio-Rad) on a
membrane (1,704,275, Bio-Rad), Ponceau S staining confirmed equal loading. The
tagged protein RPAC1 was detected by the primary antibody (sc-374443, Santa
Cruz Biotechnology), which was subsequently detected by the fluorescently labelled
secondary antibody (926-32210, Li-COR). Prestained Marker and secondary
antibody were detected at different wavelengths (Odyssey Infrared Imager Model
9120, Li-COR).
Anti-GFP pulldown from nuclear and cytosolic fractions. A total of ~7 L
POLR1C-GFP Hela cells were grown in a spinner flask (Corning) and collected by
centrifugation, yielding a cell pellet of 8.1 g (estimated total of 2.3 × 109 cells).
Nuclear extract production was based on a published protocol41. The cell pellet was
resuspended in 9.8 ml of MC Buffer (10 mM HEPES-KOH pH 7.6, 10 mM KOAc,
0.5 mM Mg(OAc)2, 5 mM dithiothreitol (DTT), 0.5 mM phenylmethylsulfonyl
fluoride (PMSF)) and incubated for 5 min on ice. Following dounce homo-
genization, nuclei and cytosolic fractions were separated by centrifugation using a
Sorvall SS34 rotor at 18,000 × g at 4 °C for 5 min. This resulted in a nuclear pellet of
5.1 g, which was resuspended with 6.7 ml ‘Roeder C Buffer’ (25% v/v glycerol, 20
mM HEPES-KPOH pH 7.9, 1.5 mM MgCl2, 0.2 mM EDTA pH 8.0, 420 mM NaCl,
0.5 mM DTT, 0.5 mM PMSF) and corresponds to 12 ml of nuclear extract. Nuclei
were lysed with a dounce homogenizer, slowly stirred at 4 °C and centrifuged in a
Sorvall SS34 rotor at 16,000 × g at 4 °C for 30 min. Nuclear extracts and cytosolic
fraction were split into fractions of 0.5 mL each.
An aliquot of nuclear extract and cytosolic fraction were each supplemented
with 500 µL wash buffer (5% v/v glycerol, 20 mM HEPES 7.8, 420 mM NaCl, 1 mM
MgCl2, 0.1 mM ZnCl, 2 mM β-mercaptoethanol, 0.5 mM PMSF) and 5 units
DNase I (Thermo Fished Scientific) followed by 30 min incubation at 4 °C in an
overhead mixer. Debris was removed by centrifugation (Eppendorf Centrifuge
5427 R, Rotor FA-45-12-17) 13k r.p.m., 4 °C, 30 min. Nuclear extracts and cytosolic
fraction were each bound to 20 µL (slurry) ‘GFP selector’ Beads (NanoTag) for 2 h
and washed twice with 0.5 mL wash buffer times and washed/eluted as described
above. Elution was carried out with 3C protease in 50 µL wash buffer at 4 °C for 2 h.
Pre-cast SDS-polyacrylamide gel electrophoresis (PAGE) gels (4–12% NuPAGE
Bis-Tris, Thermo Scientific) were loaded with 12.5 µL fractions.
Large-scale human RNA Pol purification. Large-scale cell growth was carried out
at the Cell Services Scientific Technical Platform at The Francis Crick Institute,
London. Adherent HeLa POLR1C-GFP cells were grown in DMEM-4 medium
supplemented with 1% fetal bovine serum (FCS), 1% Glutamax and 1% Penicillin/
Streptomycin. Confluent cells were collected by trypsin treatment followed by
gentle centrifugation. The cell pellet was subsequently resuspended in RPMI-1640
supplemented with 5% FCS, 1% Glutamax and 1% penicillin/streptomycin, to allow
for cell growth in suspension. Cells were expanded in suspension using a small
glass spinner flask flushed with CO2 at 37 °C. Cells were expanded to a maximum
volume of 1.2 L per growth in a 3 L glass spinner flask. Cells were grown to a
density of to 1 × 106 cells/ml with viability maintained at >90%. Following growth,
cells were collected by gentle centrifugation at room temperature. The resulting cell
pellets were washed with PBS and cells pelleted again via centrifugation. The final
cell pellets were stored at −80 °C prior to purification.
For large-scale purification of human RNA Pol, whole-cell lysate was produced
from a cell pellet derived from 20 L of HeLa cells grown to 1 × 106 cells/ml density.
The cell pellet was resuspended in lysis buffer (50 mM Tris-HCl pH 8.0, 250 mM
(NH4)2SO4, 20% v/v glycerol, 1 mM MgCl2, 10 μM ZnCl2, 10 mM β-
mercaptoethanol) and two protease-inhibitor tablets (Roche) added. Lysis was
performed through repeated passage of the cell suspension through a dounce
followed by sonication with the resulting lysate cleared through centrifugation at
28,000 × g at 4 °C for 40 min followed by filtration of the soluble fraction through
gauze. The cleared lysate was incubated with 1 ml of GFP selector beads 50% slurry
(Nanotag) pre-equilibrated in lysis buffer. Beads were incubated for 3 h at 4 °C
under continuous rotation. Beads were washed with 60× slurry volume in lysis
buffer and eluted through overnight incubation at 4 °C with 160 μl of HRV−3C
protease (Millipore) in a final volume of 2–3 ml. Following elution, the eluate was
collected through gentle centrifugation of the beads at 1000 × g and collection of
the supernatant. The beads were then washed in double the eluate volume with
wash buffer (50 mM Tris-HCl pH 8.0, 50 mM (NH4)2SO4, 1 mM MgCl2, 10 μM
ZnCl2, 10 mM β-mercaptoethanol) and the resulting wash fraction combined with
the eluate to dilute the (NH4)2SO4 to ~120 mM. The eluate mixture was further
diluted through addition of an equivalent volume of Tris buffer (50 mM Tris-HCl,
1 mM MgCl2, 10 μM ZnCl2, 10 mM β-mercaptoethanol) to reduce the final
(NH4)2SO4 concentration to ~60 mM. Next, the eluate was loaded onto a MonoQ
GL 5/50 column (GE Healthcare) and eluted in a linear gradient from 60 mM to
1M (NH4)2SO4 in 50 mM Tris-HCl pH 8.0, 1 mM MgCl2, 10 μM ZnCl2, 10 mM β-
mercaptoethanol. MonoQ purification produced two peaks corresponding to RNA
Pol I (eluting at ~380 mM (NH4)2SO4) and RNA Pol III (eluting at ~550 mM
(NH4)2SO4). Human RNA Pol III fractions were collected and diluted to a final
(NH4)2SO4 concentration of ~110 mM. The sample was then concentrated using a
Vivapsin 500 (100,000 Molecular Weight Cut Off to a final concentration of
~0.05–0.1 mg/ml. The concentrated sample was used immediately for grid
preparation.
RNA elongation and cleavage assay. Human Pol III (0.5, 1 or 2 pmol) was
preincubated with 0.25 pmol of pre-annealed minimal nucleic acid scaffold (tem-
plate DNA: 5′-CGAGGTCGAGCGTTGTCCTGGT-3′, non-template DNA: 5′-CG
CTCGACCTCG-3′; RNA: 5′-FAM-AACGGAGACCAGGAC-3′) in transcription
buffer (20 mM Hepes pH 7.8, 42–168 mM (NH4)2SO4 (hs Pol III buffer), 8 mM
MgSO4, 10 µM ZnCl2, 10% (v/v) glycerol, 10 mM DTT) for 1 h at 20 °C in a 45 µl
reaction. For RNA elongation, 10 µmol of each Nucleotide triphosphate was added
and the reaction was incubated for 1 h at 28 °C. To examine cleavage activity, the
preincubated reaction was incubated for 1 h at 28 °C without the addition of NTPs.
In the following, nucleic acid purification was examined by adding 5M NaCl to an
end concentration of 0.5 M and 800 µl 100% ethanol. After precipitation for at least
1 h at −20 °C, the sample was centrifuged for 30 min at 20,000 × g and 4 °C. The
pellet was washed with 80% ethanol and, after drying, resuspended in 1× RNA
loading dye (4 M Urea, 1× Tris-Borate-Ethylenediaminetetraacetic acid, 0.01%
bromophenol blue, 0.01% xylene cyanol). The sample was heated to 95 °C for 5
min. As control, 0.25 pmol of scaffold was treated identically, without addition of
Pol and NTPs. FAM-labelled RNA product (0.125 pmol) was separated by gel
electrophoresis (20% polyacrylamide gel containing 7M Urea) and visualized with
a Typhoon FLA9500 (GE Healthcare).
Cryo-EM sample preparation and data collection. Human Pol III cryo-EM
samples were prepared on C-Flat 1.2/1.3 (400 mesh) grids coated with a thin film of
continuous carbon prepared in house. Grids were glow discharged at 15 mA for 30
s using a PELCO EasyGlow instrument prior to sample addition. A 3 μl volume of
sample at ~0.06 mg/ml concentration was applied and incubated for 30 s at 18 °C
and 100% humidity. Grids were blotted for 1 s at blot force 1 with a 0.5 s drain time
and plunge frozen in liquid ethane using the VitroBot Mark IV system (FEI).
Data collection was carried out using a FEI Titan Krios transmission electron
microscope (Thermo Fisher) operating at 300 KeV and equipped with a Falcon III
direct electron detector (Astbury Biostructure Laboratory, University of Leeds).
Separate data collections were carried out for both untilted and 30° tilted data sets.
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All data sets were imaged using EPU automated acquisition software with the
Falcon III operating in electron counting mode at a nominal magnification of
×75,000 and a calibrated sampling of 1.065 Å/pixel. For untilted data collection,
3115 movies were collected. Movies were collected over 45 frames with a 70 s
exposure time and a total dose of 44.1 e−, giving a dose per frame of 0.98 e−/Å2 and
a dose rate of 0.63 e−/Å2/s. Data were collected over a defocus range of −1 μm to
-3μm. Tilted data collection was carried out at 30o in two separate sessions. The
first session collected 921 movies, with a total dose of 37.8 e− fractionated over 38
frames during a 70 s exposure, yielding a dose per frame of 0.99 e−/Å2 and a dose
rate of 0.54 e−/Å2/s. The second session collected 1703 movies, imaged with a total
dose of 40.6 e− fractionated over 38 frames during a 70 s exposure. This gave dose
per frame of 1.07 e−/Å2 and a dose rate of 0.58 e−/Å2/s. In both tilted data
collections, micrographs were collected using a −1.2 to −3 μm defocus range.
Cryo-EM image processing. Frame alignment and dose weighting was carried out
on-the-fly using MotionCor242. Following motion correction, CTFFIND4 imple-
mented in the cisTEM software package was used for contrast transfer function
(CTF) estimation43. Particle picking was carried out using the ab initio particle
picking option in cisTEM44 and resulting particles exported to Relion 3.145. Sub-
sequent 2D and 3D classification, refinement and post-processing steps were car-
ried out using Relion 3.1, and ab initio model generation using Cryosparc v246. For
the untilted dataset, 332,238 particles were selected, yielding a final particle set of
139,891 particles corresponding to hPol III following multiple rounds of 2D
classification. This particle subset was used to generate an initial model of the hPol
III structure using the ab initio model functionality in Cryosparc v2. Similarly,
87,075 particles were selected from 2624 30° tilted micrographs, yielding 32,787
particles following 2D classification. Both particle sets were combined generating
the merged particle set of 172,678 particles. This was subject to 3D classification in
Relion 3.1 using the Cryosparc ab inito model as a reference. Classification pro-
duced 5 classes, with a single class (class 4, containing 68,291 particles) corre-
sponding to the complete Pol molecule. This class was refined and subject to CTF
refinement. This was a sequential procedure, first correcting for trefoil and fourth-
order aberrations, followed by correction for magnification anisotropy in the sec-
ond step. In the final step, the defocus was refined on a per particle basis to correct
for errors in CTF estimation for tilted particles. Following this, a further refinement
was carried out, yielding a model at 3.7 Å resolution at the gold-standard 0.143
Fourier shell correlation (FSC) cut-off criterion. Following refinement and post
processing, the map was filtered according to the local resolution of each region
using the local resolution functionality implemented in Relion 3.1. Inspection of
the resulting density revealed poor density and low resolution of the heterotrimer
region. To improve this region, a local mask was generated and 3D classification
carried out without alignment localized to the heterotrimer. This produced 3
classes, of which 1 (containing 25,369 particles) produced a model with improved
heterotrimer density following consensus refinement. This was subject to further
CTF refinement, consensus refinement and local resolution estimation to produce
the final model reporting 4.0 Å global resolution at the 0.143 FSC cut-off criterion.
Cryo-EM model building and refinement. As an initial step, homology models
were generated for all core (RPC1, RPC2, RPC10, RPAC1, RPAC2, RPABC1,
RPABC2, RPABC3, RPABC4 and RPABC5), heterodimer (RPC4 and RPC5) and
stalk (RPC8 and RPC9) subunits using the PHYRE2 webserver47. These were
rigidly fitted into the locally filtered map using the fitted yeast apo-RNA Pol III
structure (RCSB Protein Data Bank (PDB) code: 6EU2) as a guide for the relative
positioning of the subunits in UCSF Chimera48. The placed homology models were
then fitted manually to the density using the COOT software package49, at this
stage regions not present in the EM density were removed from the model. Fol-
lowing manual fitting, the model was fitted using the real-space refinement func-
tionality in PHENIX50. The lower resolution of the more dynamic heterotrimer
region did not permit the use of this strategy for these subunits. Therefore, the
existing crystal structure of human RPC3 in complex with a fragment of RPC751
(RCSB PDB Code: 5AFQ) was structurally aligned with the yeast heterotrimer in
the yeast apo-RNA Pol III structure in UCSF Chimera. Comparison revealed a
highly similar structure and relative arrangement for the RPC3 and RPC7 regions
present in both structures. Further to this, a homology model for RPC6 was
generated using PHYRE2. This was structurally aligned in UCSF Chimera to the
yeast RPC6 subunit present in the yeast apo Pol III structure. The region of human
RPC6 consisting of residues 174–289 was selected for inclusion in the model, as
this was the region which corresponded to residues 171–271 of yeast RPC6, which
were visible in the yeast RNA Pol III apo state4. Following selection of the relevant
models, they were positioned using the yeast apo structure as a guide and then
fitted to the human EM map using the sequential fit option in UCSF chimera.
RPC5 cloning, expression and purification. Based on secondary structure pre-
dictions using PsiPred52 and HHPred programmes53, we designed 13 different
constructs of the C-terminal extension of RPC5 subunit (Uniprot ID Q9NVU0). A
PCR-based strategy was used to amplify fragments of RPC5-tWHD1, RPC5-
tWHD2 and RPC5EXT from its genomic DNA (Genscript). The constructs were
subsequently cloned into pOPINF or pOPINJ plasmids for bacterial expression or
into pACEBac1 plasmid for baculovirus-insect cells expression. Two hexahistidine-
tagged constructs that rendered high yield expression of undegraded proteins
(RPC5 (259–440) and RPC5 (556–708)) were selected for large-scale production.
Both protein constructs were expressed and purified following the same protocol.
Cells were grown at 37 °C, 200 r.p.m. in Terrific Broth to OD600= 1.5 and protein
expression was induced with 1 mM isopropyl β-D-1-thiogalactopyranoside at 20 °C
overnight. All subsequent steps were performed at 4 °C. Collected cells were
resuspended in 20 mM HEPES pH 7.9, 150 mM NaCl, 10 mM imidazole and
10 mM β-mercaptoethanol supplemented with DNAse I and two protease-inhibitor
tablets (Roche). After a 30 min incubation, the sample was sonicated and fractio-
nated by centrifugation at 20,000 r.p.m. for 40 min. Then, the soluble fraction was
loaded in a HisTrap HP 5mL affinity column (GE Healthcare) pre-equilibrated
with lysis buffer. After extensive washes of the chromatographic column, the
protein was eluted with lysis buffer supplemented with 250 mM imidazole. The
sample was diluted to 70 mM NaCl and injected into an HiTrap Heparin HP 5ml
(GE Healthcare) column equilibrated with 20 mM HEPES pH 7.9, 70 mM NaCl
and 10 mM β-mercaptoethanol. The protein was subsequently eluted using an
isocratic gradient from 70mM to 2M NaCl in 30 column volumes. Fractions
containing RPC5 constructs were identified by SDS-PAGE analysis. Cleavage of the
His-tag was performed overnight incubating the protein with 3C protease in a 1 :
50 molar ratio (3C protease: RPC5). Uncleaved His-tagged proteins were removed
by incubation of the sample with 1 ml HisPurTM (Thermo Fisher) nickel resin for
1 h at 4 °C. The cleaved protein was concentrated to 5 ml and loaded in a HiLoad
16/600 Superdex 75 pg gel-filtration column (GE Healthcare) equilibrated with 50
mM Tris-HCl pH 7.5, 150 mM NaCl and 10 mM β-mercaptoethanol. Purified
RPC5 (259–440) and RPC5 (556–708) were concentrated to 30 and 80 mg/ml,
respectively, flash-frozen and stored at −80 °C.
The expression of selenomethionine-derivatized proteins was performed in the
methionine-auxotroph Escherichia coli B834(DE3) strain (Novagen) using
SelenoMetTM medium (Molecular Dimensions) supplemented with SelenoMet
Nutrient Mix and 40 mg/l L-selenomethionine (SeMet). Purification of the proteins
was performed as described for the native proteins.
The expression of the whole C-terminal extension of RPC5 (referred as
RPC5EXT) was performed in the insect cells/baculovirus expression system. Large-
scale suspension cultures (300 mL) of High Five insect cells at 0.5 × 106 cells/ml
were grown in Insect-Xpress media (Lonza) and inoculated with P2 baculovirus
solution containing the RPC5 constructs. Proliferation arrest was assessed by
measurement of GFP production until fluorescence reached a plateau. Cells were
collected at 800 × g for 5 min and the pellets were stored at −20 °C. After a milder
sonication step, purification was performed following the protocol described above.
Finally, protein was concentrated to 10 mg/mL, flash-frozen in liquid nitrogen and
stored at −80 °C.
Crystallization, data collection and structure determination. Crystals used for
structure determination were grown from a 1 : 1 ratio solution (protein : reservoir)
using the vapour diffusion technique at 4 °C. RPC5 (259–440) crystals in
P6122 space group were obtained at 30 mg/mL after 3–4 days equilibration in 3.2 M
NaCl, 100 mM Sodium Acetate pH 4.6 and 10 mM ZnCl2. SeMet-RPC5 (259–440)
crystals in the same space group were obtained at similar conditions but required
the use of streak seeding with diluted native crystals to favour nucleation. RPC5
(556–708) crystals in P21 space group grew at 35 mg/mL in 3.2–3.8 M Ammonium
Acetate and 100 mM Bis-Tris Propane pH 6.5–7 after 2 weeks. Crystallization of
SeMet-RPC5 (556–708) protein was performed under identical conditions. All
crystals were flash-frozen in liquid nitrogen using perfluoropolyether oil (Hampton
Research) as a cryoprotectant.
A dataset from native RPC5 (259–440) was collected at 0.9198 Å wavelength in
I24 beamline of Diamond Light Source (DLS). In addition, multi-wavelength
anomalous dispersion (MAD) data collections were performed at the peak, remote
and inflection wavelengths from SeMet-derivatized crystals of RPC5 (259–440) and
RPC5 (556–708) in I03 beamline of DLS. Using the MAD dataset, an initial model
of SeMet-RPC5 (259–440) at 2.7 Å was determined with the SHELXC/D/E suite
from the HKL2Map programme (for phase determination) and the Buccaneer
software (for model building). The native structure at 2.2 Å was solved by
molecular replacement using the initial SeMet model as a search reference in
PHENIX.automr. Subsequent refinement was performed using COOT and
PHENIX suites. The structure of RPC5 (556–708) at 1.48 Å was solved from the
SeMet data sets using HKL2Map and Buccaneer programmes, and further refined
to acceptable Rfree/Rwork values with COOT and PHENIX. Protein secondary
structure assignment from the atomic coordinates was performed using STRIDE54.
RPC5 SAXS data collection and processing. SAXS data collection was carried
out at the SWING small- and wide-angle scattering beamline, SOLEIL Synchro-
tron, Saint Aubin, France. Purified RPC5EXT (164 μM), tWHD1 (922 μM) and
tWHD2 (3691 μM) were passed through a Bio SEC-3 HPLC column (Agilent) at
0.2 ml/min in 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10 mM β-mercaptoethanol
with protein elution monitored using A280. Data were collected using an Eiger X
4M detector (Dectris) at a 2 m distance, using a q-range of 0 < q < 0.68 Å−1. Data
were reduced and buffer subtraction performed at the beamline. Data analysis was
carried out using the ScÅtter software package for determination of radius of
gyration (Rg), P(r) distribution, particle maximum dimension (Dmax) parameters
and for qualitative flexibility analysis (through generation of Rg-Normalized
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Kratky, SIBLYS and Porod-Debeye plots)55. Volumetric bead modelling was per-
formed using the DAMMIN software package56. Briefly, ab inito bead models were
calculated using DAMMIN ten times for each construct, fitting over the q-range of
0 < q < 0.25 Å−1. The resulting bead models were averaged and filtered using the
DAMAVER package57, generating the final bead model reconstruction.
Comparison of the theoretical scatter profiles of the determined crystal
structures for the tWHD1 and tWHD2 constructs was performed using the
CRYSOL package for structural validation58. Modelling of the entire RPC5 C
terminus (RPC5EXT) was performed using Ensemble Optimisation (EOM)
analysis from the ATSAS package59 of the RPC5EXT SAXS data using the q-range
0 < q < 0.2 Å−1. The determined tWHD1 and tWHD2 crystal structures were
defined as rigid bodies in the RPC5 C-terminal sequence, with EOM analysis
modelling the intervening 115 amino acid linker as dummy atoms, generating a
pool of 10,000 random structural conformations from which the ensemble was
selected to sample the continuous structural heterogeneity.
Cell culture. HEK293T cells (a kind gift from Dr Sebastien Guettler) were cultured in
DMEM supplemented with 10% heat-inactivated FBS and 1% penicillin/streptomycin
at 37 °C in 5% CO2. For transient knockdown, 20 nM siRNA of either ONTAR-
GETplus siRNA for RPC5 (Horizon Discovery) or AllStars negative control siRNA
(Qiagen) was used per well. This was transfected using Lullaby transfection reagent
(Oz Biosciences) as per the manufacturers’ instructions. The sequences for each
RPC5 siRNA are as follows: 5′-UGGAUAAGGCUGACGCCAA-3′, 5′-GGGAGCA
GAUUGCGCUGAA-3′, 5′-CGACGAGACCAGCACGUAU-3′, 5′-CCUCGAUGAC
CUACGAUGA-3′. For transient overexpression of RPC5 (HA-tagged full-length
ΔtWHD2 or ΔC), DNA (1.5 μg) was transfected in using Fugene HD transfection
reagent (Promega) as per the manufacturers’ instructions.
Antibodies. The following primary antibodies were used: POLR3A (ab96328,
Abcam), POLR3B (ab137030, Abcam), POLR3D (ab86786, Abcam), POLR3E
(ab134560, Abcam), HA-tag (ab9110, Abcam), GAPDH (MAB374, diluted 1 : 5000
for western blotting, Merck) and RPA40 (sc-374443, Santa Cruz). The following
secondary antibodies were used: anti-rabbit IgG (H+ L) DyLightTM 800 4× PEG
conjugate (#5151, Cell Signalling Technology) and anti-mouse IgG (H+ L)
DyLightTM 680 (#5470, Cell Signalling Technology). All antibodies were used at a
dilution of 1 : 1000, unless otherwise stated.
Co-immunoprecipitation and western blotting. HEK293T cells were seeded into
10 cm plates in the presence of siRNA. After 24 h, they were subsequently trans-
fected with RPC5 (HA-tagged full-length ΔtWHD2 or ΔC) and maintained for a
further 24 h. Cells were lysed in RIPA buffer and co-immunoprecipitation was
performed using PierceTM anti-HA magnetic beads (Thermo Fisher Scientific).
HA-tagged proteins were eluted from the beads through addition of NuPAGETM
LDS 4× sample buffer and boiling the samples for 10 min. For whole-cell lysates,
cells were lysed in RIPA buffer and then NuPAGETM LDS 4× sample buffer
(Thermo Fisher Scientific) plus NuPAGETM 10× sample reducing agent (Thermo
Fisher Scientific) was added before being boiled for 5 min. SDS-PAGE was sub-
sequently performed on the lysates in 4–12% Bis-Tris protein gels, transferred to
nitrocellulose membrane, blocked for 1 h in 5% milk/Tris-buffered saline/0.1%
Tween20 and probed with primary antibody overnight at 4 °C. Secondary anti-
bodies were incubated for 1 h at room temperature in the dark and detected using
the Odyssey-CLx fluorescence imaging system (LI-COR Biosciences). All
uncropped gel images are available in the source data file.
Cycloheximide chase assay. HEK293T cells were seeded into six-well plates in the
presence of siRNA. After 24 h, they were subsequently transfected with either
RPC5 (HA-tagged full length or ΔC) and maintained for a further 24 h. Cyclo-
heximide was then added at a concentration of 300 μg/ml and cells lysed at regular
time points (every 2 h, up to a maximum of 8 h) using RIPA buffer and lysates were
analysed via western blotting, as previously stated. All uncropped gel images are
available in the Source Data file.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
The electron density reconstructions and final model were deposited with the Electron
Microscopy Data Base under accession code number EMD-11904 and with the Protein
Data Bank (PDB) under accession code 7AST. The PDB accession numbers for the
atomic coordinates and structure factors of the RPC5EXT tWHD1 and tWHD2 crystal
structures reported in this paper are 7ASU and 7ASV, respectively. The RNA Pol models
used in this study are available from PDB under accession codes 5FYW, 5W66, 6EU0,
6EU2 and 6EU3. Source data are provided with this paper.
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